PRF1 and neoplasm: -associated antigen-4 (CTLA-4) pathways interacting with inhibitory antibodies to enable activated T cells to release cytokines, perforins, granzymes, etc., to kill tumor cells in a rapidly evolving immunotherapeutic regimen (47).